Antisense Therapeutics Limited (ASX:ANP) has announced that it intends to conduct a double-blind, placebo-controlled six-month dosing trial of ATL1102 followed by a six-month open-label phase 2b trial in non-ambulant boys with Duchenne’s Muscular Dystrophy. …
Antisense Therapeutics announces revised clinical development plan for ATL1102
September 8, 2022 Australian Biotech
Latest Video
New Stories
-
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News -
The minister and the US-based industry have a lot in common, including their criticisms of the PBS
March 20, 2025 - - Latest News -
Sigma releases final pre-merger full-year result, confirming impact of CW supply contract
March 20, 2025 - - Latest News -
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News